American Biogenetic Sciences' (ABS) and Roche collaborate on thrombus precursor protein (TpP) test
This article was originally published in Clinica
Roche is to collaborate in the development of American Biogenetic Sciences' (ABS) active thrombosis test (see Clinica No 674, p 15). The two companies will adapt the thrombus precursor protein (TpP) test to a latex agglutination format for use with Roche's automated diagnostics systems. ABS will manufacture kits in exchange for a percentage of selling price plus a royalty. The test will also be sold to other companies on a profit-sharing basis.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.